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Abstract Formation of sphingosine-1-phosphate (SPP) by
sphingosine kinase serves as a signalling pathway for various
membrane receptors. Here, we show that membrane depolarisa-
tion is another mechanism by which this pathway can be
activated. Formation of [3H]SPP as well as levels of endogenous
SPP were rapidly and transiently increased in PC12 pheochro-
mocytoma cells depolarised with high KCl. Time course and
maximum were similar to those induced by bradykinin.
Depolarisation-induced SPP production was also observed in
RINm5F insulinoma cells, dependent on extracellular Ca2+ and
fully suppressed by verapamil, thus apparently caused by Ca2+
influx via voltage-gated Ca2+ channels. Studies with sphingosine
kinase inhibitors and overexpression of sphingosine kinase
revealed a partial contribution of this pathway to depolarisa-
tion-induced noradrenaline release and Ca2+ increase. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Sphingosine-1-phosphate (SPP), produced from sphingosine
by sphingosine kinase, acts as extracellular lipid mediator
binding to and activating speci¢c G-protein-coupled receptors
(GPCRs) of the EDG receptor family [1,2]. There is, however,
also ample evidence that SPP can serve as intracellular signal-
ling molecule involved in Ca2 mobilisation and mitogenesis
[3^6]. Several plasma membrane receptors, such as antigen
receptors, receptor tyrosine kinases and various GPCRs,
have been reported to stimulate sphingosine kinase activity
and to increase intracellular SPP accumulation in diverse
cell types [7]. Inhibition of sphingosine kinase by DL-threo-di-
hydrosphingosine (tDHS) or N,N-dimethylsphingosine (DMS)
attenuated or blocked some cellular responses to these recep-
tors, while others were not a¡ected [4,8^10]. Speci¢cally, these
data and additional experimental approaches, including over-
expression of sphingosine kinases, provided evidence for an
involvement of intracellular SPP in stimulation of mitogenesis
and inhibition of apoptosis [3,11]. Furthermore, microinjected
SPP has been shown to cause Ca2 release from intracellular
stores, in a manner similar to inositol-1,4,5-trisphosphate and
independent of SPP receptors [4]. Together with the ¢ndings
that receptor-induced intracellular SPP production is very fast
and sphingosine kinase inhibitors attenuate Ca2 signalling by
these receptors, it was proposed that intracellular SPP pro-
duction can serve as a pathway for intracellular Ca2 release
[4,6^8,10,12].
Although two mammalian sphingosine kinases have been
cloned recently [13^17], very little is known how these en-
zymes are activated by membrane receptors. Protein kinase
C (PKC) and cyclic AMP have been reported to regulate
sphingosine kinase activity in certain cell types [7]. Interest-
ingly, there are independent reports on the Ca2 dependence
of sphingosine kinase activation [18,19]. In HL-60 cells, intra-
cellular SPP production was stimulated by Ca2 ionophores,
and GPCR agonist (fMLP or ATP)-induced SPP production
was inhibited by chelation of intracellular Ca2 [18]. Similarly,
in TRMP cells, sphingosine kinase activity was enhanced by
intracellular Ca2 release induced by thapsigargin, and chela-
tion of intracellular Ca2 blocked the stimulatory e¡ect of
platelet-derived growth factor [19]. These ¢ndings led us to
investigate whether intracellular SPP production can be in-
duced by Ca2 in£ux via voltage-gated Ca2 channels, a ma-
jor mechanism for intracellular Ca2 increase in excitable
cells. We demonstrate here that, similar to the GPCR agonist
bradykinin, KCl depolarisation of PC12 pheochromocytoma
cells leads to rapid and transient SPP production, apparently
caused by Ca2 in£ux via voltage-gated Ca2 channels. Fur-
thermore, evidence is provided suggesting that the sphingosine
kinase/SPP pathway contributes, at least in part, to the depo-
larisation-induced neurotransmitter release in these cells.
2. Materials and methods
2.1. Materials
D-erythro-[3-3H]Sphingosine (20 Ci/mmol) and L-[ring-2,5,6-3H]-
noradrenaline (55 Ci/mmol) were purchased from NEN Life Science
Products (Ko«ln, Germany). SPP, tDHS and DMS were from Biomol
(Hamburg, Germany), ionomycin, Go« 6976 and staurosporine from
Calbiochem-Novabiochem (Bad Soden, Germany), and bradykinin,
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verapamil and fatty acid-free bovine serum albumin (BSA) from
Sigma (Deisenhofen, Germany). All other materials were from previ-
ously described sources [4,10,20]. Stock solutions of tDHS and
DMS were made in methanol and further diluted in 1 mg/ml fatty
acid-free BSA. The respective methanol/BSA solution was used as
control.
2.2. Cell culture and transfection
PC12 cells and RINm5F cells were cultured in DMEM/F12 and
RPMI-1640 medium, respectively, each supplemented with 10% (v/v)
foetal bovine serum, 100 U/ml penicillin G and 0.1 mg/ml streptomy-
cin, in a humidi¢ed atmosphere of 5% CO2/95% air at 37‡C. Transient
transfection of PC12 cells was performed with 100 Wg DNA of
pcDNA3.1 or murine sphingosine kinase-1 (SPK1, [13]) per 14.5-cm
dish, respectively, using the calcium phosphate precipitation method.
Overexpression of SPK1 was con¢rmed by immuno£uorescence mi-
croscopy using an antibody against the N-terminal myc-tag [21].
2.3. Measurement of [3H]SPP formation
Formation of [3H]SPP from [3H]sphingosine was measured as re-
ported before [4,10]. Cells were washed with Hanks’ balanced salt
solution (HBSS), containing 118 mM NaCl, 5 mM KCl, 1 mM CaCl2,
1 mM MgCl2, 5 mM glucose and 15 mM HEPES, pH 7.4, and
detached by a bu¡er stream. The reactions were started by addition
of 100 Wl of cell suspension (0.5U105 cells) to 100 Wl of a reaction
mixture containing 2 mg/ml BSA, 1 WCi/ml [3H]sphingosine and the
indicated agonists in HBSS. Incubation was for the indicated periods
of time at 37‡C. Reactions were stopped by addition of 3 ml meth-
anol/chloroform (2/1), and lipids were extracted for 60 min at 37‡C.
After centrifugation for 10 min at 2000Ug, the lipids were dried down
in a SpeedVac vacuum centrifuge, dissolved in a small volume of
methanol and applied to Silica gel 60 thin layer chromatography
(TLC) plates together with sphingosine and SPP standards. The lipids
were separated in 1-butanol/acetic acid/water (3/1/1), visualised with
ninhydrin, spots were scraped o¡, and radioactivity was measured by
liquid scintillation counting.
2.4. SPP mass determination
Endogenous SPP levels were determined as described before [20].
Brie£y, PC12 cells were suspended in 1 ml HBSS (107 cells/ml) and
stimulated with bradykinin or KCl for the indicated periods of time at
37‡C. Reactions were stopped by the addition of 1 ml methanol con-
taining 2.5 Wl concentrated HCl. Dihydro-SPP (50 pmol) was added
and lipids were extracted by addition of 1 ml chloroform and 200 Wl
4 M NaCl. For alkalisation, 100 Wl 3 N NaOH were added. After
centrifugation (300Ug, 5 min), the alkaline aqueous phase was trans-
ferred into a siliconised glass tube, and the organic phase was re-
extracted with 0.5 ml methanol, 0.5 ml 1 M NaCl and 50 Wl 3 N
NaOH. The aqueous phases were combined, acidi¢ed with 100 Wl
concentrated HCl and extracted twice with 1.5 ml chloroform. The
combined organic phases were evaporated, and the dried lipids were
dissolved in 275 Wl methanol/0.07 M K2HPO4 (9:1) by rigorous vor-
texing and sonication on ice for 5 min. A derivatisation mixture of 10
mg o-phthaldialdehyde, 200 Wl ethanol, 10 Wl 2-mercaptoethanol and
10 ml 3% boric acid was prepared and adjusted to pH 10.5 with
potassium hydroxide. 25 Wl of this derivatisation mixture was added
to the resolved lipids for 15 min at room temperature. The derivatives
were analysed by a Merck Hitachi LaChrom HPLC system (Merck
Hitachi, Darmstadt, Germany) using a RP 18 Kromasil column
(Chromatographie Service, Langerwehe, Germany) kept at 35‡C. Sep-
aration was done with a gradient of methanol and 0.07 M K2HPO4
[20] and the o-phthaldialdehyde derivatives were detected by £uores-
cence. Resulting pro¢les were evaluated using the Merck system man-
ager software. The recovery of SPP was calculated using dihydro-SPP
as standard [20].
2.5. Noradrenaline release
PC12 cells grown on 24-well plates or 35-mm dishes were incubated
with 0.1 WCi/ml [3H]noradrenaline in HBSS or serum-free medium
containing 1 mM ascorbic acid for 90^120 min at 37‡C and washed
twice. Thereafter, the cells were pretreated with or without tDHS,
DMS or PKC inhibitors dissolved in HBSS for the indicated periods
of time. Stimulation with KCl or other stimuli followed for 10 min at
37‡C. Released [3H]noradrenaline was measured in the supernatant,
while for measurement of cellular [3H]noradrenaline content, the re-
maining cell pellet was lysed in 1% (w/v) sodium dodecyl sulphate,
followed by liquid scintillation counting.
2.6. Measurement of intracellular Ca2+ concentration
Intracellular free Ca2 concentration ([Ca2]i) was determined with
the £uorescent Ca2 indicator dye fura-2 in a Hitachi spectro£uorim-
eter as described before [4]. Brie£y, cell monolayers were washed with
HBSS, and cells were detached by a bu¡er stream. Suspended cells
were loaded with 1 WM fura-2/AM for 1 h at 37‡C in HBSS. There-
after, cells were washed twice, resuspended at a density of 1U106
cells/ml and used for £uorescence measurements at room temperature
within the next hour.
2.7. Data analysis and presentation
Data are mean þ S.E.M. from the indicated number (n) of experi-
ments or mean þ S.D. from a representative experiment with the in-
dicated number (n) of replicates. Statistical signi¢cance was calculated
using the Prism program (GraphPad Software). Two groups of values
were compared by two-tailed t-test, while more than two groups of
values were compared by one-way analysis of variance followed by
Dunnett’s multiple comparison test.
3. Results
To study whether depolarisation-induced Ca2 in£ux can
stimulate sphingosine kinase activity and SPP formation in
excitable cells, PC12 pheochromocytoma cells were treated
with high extracellular K in the presence of 1 mM extracel-
Fig. 1. Stimulation of [3H]SPP formation by bradykinin and KCl depolarisation. [3H]Sphingosine was added to PC12 cells together with 10
WM bradykinin or 60 mM KCl, and formation of [3H]SPP was determined at the indicated periods of time. Data are mean þ S.E.M. of 4^9
(bradykinin) or 3^5 experiments (KCl) and given as fold increases over basal [3H]SPP formation, amounting to 150 þ 24 cpm (bradykinin,
n = 8) or 241 þ 21 cpm (KCl, n = 4) at 30 s. Please note the di¡erent time scales in left and right panel. **P6 0.01.
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lular Ca2. As shown in Fig. 1 (right panel), the addition of
KCl (60 mM) rapidly and transiently increased formation of
[3H]SPP from [3H]sphingosine. The maximum increase was
observed at 30^60 s and amounted to V1.5-fold above basal
values. Addition of the GPCR agonist, bradykinin (10 WM),
caused a similar increase (by V1.7-fold) in [3H]SPP forma-
tion, with a maximum at 30 s (Fig. 1, left panel). With either
stimulus, high KCl and bradykinin, basal values of [3H]SPP
were reached again after 120 s. Since measurement of [3H]SPP
formation from added [3H]sphingosine provides no informa-
tion about the actual intracellular SPP levels, SPP mass deter-
minations were performed. Basal SPP levels in PC12 cells
were V50 pmol/108 cells, in agreement with own previous
results [20] and with data obtained by enzymatic measurement
of SPP (90 pmol/108 cells) [22]. Addition of bradykinin (10
WM) and high KCl (60 mM) rapidly increased SPP levels, by
maximally V1.3- and V1.5-fold, respectively (Fig. 2). As
observed with [3H]SPP formation, the increase in SPP levels
induced by either bradykinin or high KCl were transient,
although with slightly di¡erent kinetics for time to peak and
decline to basal values.
Elevation of intracellular SPP formation induced by high
KCl was completely dependent on in£ux of extracellular
Ca2. First, in the absence of extracellular Ca2, KCl (60
mM) failed to enhance [3H]SPP formation (0.99 þ 0.04-fold
compared to unstimulated cells at 30 s of stimulation,
mean þ S.D., n = 4, data not shown). Second, pretreatment
of PC12 cells with the Ca2 channel blocker, verapamil (50
WM, 10 min), fully suppressed the KCl-induced [3H]SPP pro-
duction (Fig. 3, left panel), indicating that it is caused by Ca2
in£ux via voltage-gated Ca2 channels. The Ca2 dependence
of SPP formation in PC12 cells was furthermore corroborated
by the ¢nding that treatment of the cells with the Ca2 ion-
ophore, ionomycin (1 WM), for 30 s increased [3H]SPP for-
mation by 1.82 þ 0.12-fold (mean þ S.D., n = 3, data not
shown). A ¢rst hint that depolarisation-induced SPP produc-
tion is a rather general phenomenon in excitable cells was
obtained with the insulinoma cells RINm5F. Similar as in
PC12 cells, addition of KCl (60 mM) for 30 s to RINm5F
cells increased [3H]SPP formation by V1.3-fold (Fig. 3, right
panel).
Since elevation of intracellular SPP by KCl depolarisation
was rapid, we examined whether it contributes to the rapid
process of depolarisation-induced noradrenaline release. As
Fig. 2. Elevation of endogenous SPP levels by bradykinin and KCl depolarisation. PC12 cells were stimulated with 10 WM bradykinin or 60
mM KCl for the indicated periods of time. Intracellular SPP mass was determined as described in Section 2. Data are mean þ S.E.M. of three
experiments each. Basal SPP levels were 50 þ 9 pmol/108 cells. **P6 0.01.
Fig. 3. Left panel: Inhibition of depolarisation-induced SPP production by verapamil. PC12 cells were incubated for 10 min without (control)
and with 50 WM verapamil before stimulation of the cells for 30 s without (basal) and with 60 mM KCl and measurement of [3H]SPP forma-
tion. Data are mean þ S.E.M. of four experiments. Right panel: Depolarisation-induced SPP production in RINm5F cells. Formation of
[3H]SPP was measured in RINm5F cells treated for 30 s without (basal) and with 60 mM KCl. Data are mean þ S.E.M. of three experiments.
***P6 0.001; **P6 0.01.
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shown in Fig. 4A,B, pretreatment of PC12 cells with the
sphingosine kinase inhibitors, tDHS and DMS, concentra-
tion-dependently reduced KCl-induced [3H]noradrenaline re-
lease. Inhibition by tDHS was signi¢cant at 20 WM and
amounted to maximally 30^40% (after subtraction of basal
release). DMS, which by itself slightly elevated [3H]nor-
adrenaline release at 20^40 WM, also signi¢cantly reduced
KCl-stimulated [3H]noradrenaline release, at 10 WM by
V35%. As sphingolipids, including sphingosine and tDHS,
can inhibit PKC, we studied whether prototypical PKC inhib-
itors mimicked the e¡ects of the sphingosine kinase inhibitors.
However, pretreatment of the cells for 30 min with 100 nM
Go« 6976 or 100 nM staurosporine did not a¡ect KCl-induced
[3H]noradrenaline release, amounting to 97 þ 5% and
116 þ 3% of untreated cells, respectively (mean þ S.D., n = 3,
data not shown). tDHS completely inhibited KCl-stimulated
[3H]SPP formation (Fig. 4C). Thus, the only partial inhibi-
tion of KCl-induced [3H]noradrenaline release was not due
to an incomplete inhibition of sphingosine kinase but rather
re£ects the partial contribution of intracellular SPP to the
overall transmitter release. Further evidence for a role of
sphingosine kinase in [3H]noradrenaline release was ¢nally
obtained by overexpression of murine SPK1. KCl-stimulated
[3H]noradrenaline release was clearly enhanced in PC12 cells
overexpressing SPK1 (Fig. 4D).
Most important, extracellularly applied SPP (1 WM) or
sphingosylphosphorylcholine (SPC; 10 WM) had no e¡ect on
noradrenaline release (Fig. 5), indicating that intracellularly
produced SPP does not act via plasma membrane SPP recep-
tors after being released from the cells. Furthermore, extra-
cellularly applied SPP (1 WM) had no e¡ect on [Ca2]i in PC12
cells (data not shown). Since intracellular SPP formation ap-
parently plays a role in cellular Ca2 homeostasis [4,6^
8,10,12], we also examined the e¡ect of sphingosine kinase
inhibitors on KCl-induced [Ca2]i increase and found that it
was inhibited (Fig. 5). As in KCl-induced [3H]noradrenaline
release, staurosporine rather enhanced than inhibited KCl-in-
duced [Ca2]i increase, which amounted to 126 þ 12% of con-
trol values after pretreatment with 100 nM staurosporine for
30 min (mean þ S.E.M., n = 3, data not shown), indicating that
the inhibitory e¡ect of the sphingosine kinase inhibitors was
not due to PKC inhibition.
Fig. 4. Role of sphingosine kinase in depolarisation-induced noradrenaline release. A and B: Inhibition of KCl-induced [3H]noradrenaline re-
lease by sphingosine kinase inhibitors. PC12 cells loaded with [3H]noradrenaline were treated for 10 min with the indicated concentrations of
tDHS or DMS before stimulation of the cells for 10 min without (basal) and with 30 mM KCl. Data are mean þ S.E.M. of 3^5 experiments
and expressed as % of [3H]noradrenaline release induced by KCl in the absence of inhibitor, which varied between 1000 and 5000 cpm/dish. C:
Inhibition of KCl-induced [3H]SPP formation by the sphingosine kinase inhibitor, tDHS. PC12 cells pretreated for 10 min with tDHS or the
respective solvent were stimulated for 30 s with 60 mM KCl, and production of [3H]SPP was determined as described above. Data are
mean þ S.D. of a representative experiment performed in quadruplicate. D: Enhancement of KCl-induced [3H]noradrenaline release by overex-
pression of SPK1. PC12 cells, transiently transfected with SPK1 or control vector, respectively, and loaded with [3H]noradrenaline, were stimu-
lated for 10 min with the indicated concentrations of KCl. Data are mean þ S.D. of a representative experiment performed in triplicate and ex-
pressed as % of cellular [3H]noradrenaline content. **P6 0.01.
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4. Discussion
Rapid activation of sphingosine kinase and intracellular
SPP formation has been reported during the last few years
for a wide variety of plasma membrane receptors in diverse
cell types [4,6^12,18,19,23]. We demonstrate here for the ¢rst
time that SPP formation can also be triggered by depolarisa-
tion of excitable cells, using two distinct methods which pro-
vided very similar results. Depolarisation of PC12 cells with
high K caused an increase in [3H]SPP formation from exog-
enous [3H]sphingosine as well as an elevation of endogenous
SPP levels, both occurring with a similar time course and
magnitude. Comparison of the two methods revealed that
the application of exogenous radioactive substrate apparently
mimics the physiological situation quite well. The slightly de-
layed peak response and the slower decline of elevated SPP
levels compared to [3H]SPP formation is probably due to a
more sustained availability of endogenous sphingosine. Simi-
lar observations were made with the GPCR agonist, bradyki-
nin, known to act via B2 receptors in PC12 cells [24] and
shown before to stimulate sphingosine kinase in HEK-293
cells overexpressing this receptor [25]. Furthermore, KCl de-
polarisation of PC12 cells increased SPP formation as e⁄-
ciently as bradykinin, and this stimulation was in the range
of that reported for diverse plasma membrane receptors in
other cell types [4,8,10,12,18,19,23].
Depolarisation-induced increase in SPP production in PC12
cells was dependent on extracellular Ca2 and fully suppressed
by the Ca2 channel blocker, verapamil, thus apparently
caused by Ca2 in£ux via voltage-gated Ca2 channels. KCl
depolarisation increased SPP production also in RINm5F in-
sulinoma cells, suggesting that this is a more general phenom-
enon in excitable cells. As receptor-induced sphingosine kinase
stimulation and SPP production is apparently also dependent
on intracellular Ca2 [18,19] and intracellular SPP can cause
Ca2 release from intracellular stores [4,6], the data suggest
that the sphingosine kinase pathway may serve as a Ca2-
induced Ca2 release mechanism. In agreement with such a
hypothesis, we show here that treatment of PC12 cells with
the sphingosine kinase inhibitors, tDHS and DMS, attenuated
the depolarisation-induced [Ca2]i increase. However, this re-
duction could also be due to inhibition of Ca2 in£ux. The
Ca2 release-activated Ca2 current (ICRAC) in RBL cells was
shown to be inhibited by sphingosine, and it was proposed
that activation of sphingosine kinase might, by metabolising
sphingosine, lead to disinhibition of ICRAC channels [26] ; this
could also be true for voltage-gated Ca2 channels in PC12
cells.
Previous studies in PC12 cells suggested that sphingosine
kinase and its product SPP are involved in cell di¡erentiation
and survival in these cells [27,28]. The results presented in this
study suggest a role for the sphingosine kinase pathway in
neurotransmitter release. Treatment of PC12 cells with the
sphingosine kinase inhibitors, tDHS and DMS, which have
been widely used to study the cellular function of sphingosine
kinase [4,8,10,18,29], reduced the KCl-induced noradrenaline
release by about 30%, suggesting that intracellular SPP for-
mation contributes to a signi¢cant extent to overall catechol-
amine release. Furthermore, overexpression of SPK1 en-
hanced KCl-induced noradrenaline release. With regard to
the mechanism by which intracellular SPP enhances transmit-
ter release, it was excluded that it is secreted and acts as
autocrine extracellular mediator, which however can occur
in other contexts [30]. Instead, we assume that the intracellu-
larly formed SPP acts by enhancing depolarisation-induced
[Ca2]i increase (see above). Further studies are needed to
de¢ne the exact roles of sphingosine kinase and intracellular
SPP in neurotransmitter release and depolarisation-induced
[Ca2]i increase.
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